NY-ESO-1 is known as a cancer/testis antigen and widely expressed in 10% to 50% of various tumors of different origins including prostate, breast, lung, melanoma, thyroid, squamous head and neck, as well as 70% to 80% of synovial cell sarcomas. Moreover, NY-ESO-1 expression is only restricted in adult testis and absent in normal somatic cells. Recent studies demonstrate that highly expressed NY-ESO-1 is mostly found in patients with relapsing multiple myeloma (MM) or cytogenetic abnormality. Spontaneous NY-ESO-1 antibodies and specific T cells are detected in NY-ESO-1 positive patients, which indicate NY-ESO-1 as a potent target for anti-MM immunotherapies.
Anti-NY-ESO-1 CAR-T Cell Therapy
A number of pilot clinical trials have been initiated for evaluation NY-ESO-1 specific CAR-T therapies in patients with different carcinomas. A phase I/II clinical trial reports that NY-ESO-1 targeted T cells showed encouraging responses to multiple myeloma patients receiving autologous stem cell transplant. These results suggest that the engineered T cells are safe and have extended persistence correlated with clinical activity.
Mechanisms of action of therapeutic antibodies for cancer.
Molecular Immunology,2015. 67(2), 28-45.
Our technical team has extensive knowledge and experience for in vivo model development. All animal experiments are monitored under an approved Institutional Animal Care and Use Committee (IACUC) protocol. Creative Biolabs provides various xenograft models of human carcinoma.
Human colon carcinoma model
Colon carcinoma cells CT26 are transfected to stably express NY-ESO-1 and subcutaneously injected into immunocompromised mice in right or left flank, followed by CAR-T cells treatment when tumor sizes meet certain criteria.
Xenograft model of human myeloma
NOD/SCID mice receive MM cell U266 or U266/Luc expressing cells via tail vein injection (or subcutaneous injection) and engineered T cells in same administration route. Tumor growth is monitored by intraperitoneally injection of D-luciferin and read in image xenograft imaging system.
In vivo Assay Parameters and Techniques
Creative Biolabs offers comprehensive services to test NY-ESO-1 targeted CAR-T therapy in preclinical tests. All tests are conducted by well-trained technicians and strike to milestone of timeline.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability and bio-distribution are evaluated by bioluminescence imaging, immunochemistry staining and real-time PCR
Pilot tolerated evaluation: route of administration, dosage, MTD
Clinical observation: body weight, food consumption, behavior and pathological signs
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
GLP-Compliant Preclinical Test
All our experiments are performed by well-trained and experienced technicians in a GLP-compliant and IACUC-regulated facility.
Creative Biolabs fully understands researches of adoptive T cell therapy targeting NY-ESO-1 are time-consuming and costly. With our highly experienced technical groups and state-of-the-art facilities, we can accelerate these studies by providing our top-quality in vivo tumor models and efficient analyzing services.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell as a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE